StockNews.AI
DTIL
StockNews.AI
151 days

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025

1. Precision BioSciences will release Q4 and FY2024 financial results on March 26, 2025. 2. The update may provide insights into the ARCUS® platform's development progress.

Earnings
+1.68%Current Return
VS
-0.27%S&P 500
$5.3603/21 07:21 AM EDTEvent Start
$5.4503/24 07:28 AM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Neutral?

The upcoming financial results and business update are expected; historical releases have had limited market impact.

How important is it?

Investors might want to gauge performance trends; however, no transformative news is provided.

Why Short Term?

Immediate relevance due to the financial results publication scheduled for March 2025.

Related Companies

CRSPSGENEDIT
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, including gene elimination, gene insertion, and gene excision programs, today announced that it will publish financial results for the fourth quarter and fiscal year 2024 and provide a business update on March 26, 2025. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical.

Related News